- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Top 3 Canadian Pharma Stocks (Updated April 2024)
Canada’s pharma industry is a key contributor to the global pharma market. Here are the top Canadian pharma stocks by share price performance over the past year.
From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.
In Q1, market watchers kept a close eye on pharma companies vying for the next major innovation.
Here the Investing News Network lists the top Canadian pharma stocks on the TSX and TSXV by year-on-year gains. All data was compiled on April 16, 2024, using TradingView’s stock screener, and the companies considered had market caps above C$100 million at that time. Read on to learn about what's been driving their share prices.
1. Cipher Pharmaceuticals (TSX:CPH)
Year-on-year gain: 161.29 percent; market cap: C$223.89 million; current share price: C$8.91
Cipher Pharmaceuticals is a specialty pharma company with a diverse portfolio of treatments, including a range of dermatology and acute hospital care products. The company has out-licensed some of its offerings as well.
In addition to its current portfolio, Cipher has acquired the Canadian rights to two new dermatology treatments currently undergoing Phase III clinical trials: MOB-015 for the treatment of nail fungus, and CF-101 for the management of moderate to severe plaque psoriasis. A Phase III COMFORT study of CF-101 has been completed, with a pivotal Phase III study due to start in early 2024; results are expected by 2026. MOB-015 trial results are expected in January 2025. The company is also conducting proof-of-concept studies on DTR-001, a topical treatment for removing tattoos.
On March 14, the company released its 2023 financial and operating results, showing a 2.5 percent increase in gross profit compared to the previous year and EBITDA of US$12 million, consistent with 2022.
Cipher began trading on the OTCQX Best Market under the symbol CPHRF on January 29.
2. Bausch Health Companies (TSX:BHC)
Year-on-year gain: 20.22 percent; market cap: C$4.34 billion; current share price: C$12.07
Bausch Health Companies, formerly Valeant Pharmaceuticals International, is one of the largest pharma companies in Canada. Its headquarters are in Laval, Quebéc, where the company has research and laboratory facilities equipped with state-of-the-art equipment and technology that play a crucial role in driving its research and development efforts.
Its range of offerings includes treatment options for gastrointestinal, neurological and dermatological conditions, as well as products for vision care and dentistry. In March, the company and its gastroenterology business, Salix Pharmaceuticals, announced that the two would be jointly supporting a Phase II study of Relistor, an opioid antagonist, in oral cavity squamous cell carcinoma. Bausch serves the Canadian and US markets, as well as a number of regions in Europe, the Middle East, Africa, the Caribbean, Latin America and the Asia Pacific region.
On April 3, the company announced that Uceris, an aerosol foam used to treat distal ulcerative colitis, would be available to patients in Ontario, Quebéc, Saskatchewan, New Brunswick and Nova Scotia through the provinces' public drug plans. Its acne vulgaris treatment PrARAZLO recently became available to patients through the BC PharmaCare public drug plan. Bausch's first quarter results are expected on May 2.
3. Biosyent (TSXV:RX)
Year-on-year gain: 11.91 percent; market cap: C$102.14 million; current share price: C$8.55
BioSyent is a specialty pharma company focused on improving patients' lives by licensing and acquiring innovative pharma products that are proven to be safe and effective with a track record of improving patient outcomes.
The company's subsidiary, known as BioSyent Pharma, offers a diverse range of healthcare products, including over-the-counter, behind-the-counter and prescription options.
On April 3, the annual Survey on OTC Counselling and Recommendations named FeraMAX, the company’s pediatric-friendly iron supplement, Canada's best oral iron supplement for the ninth consecutive year.
A couple of weeks later, on April 15, BioSyent Pharma extended its agreement with its European partner, allowing the BioSyent subsidiary to continue selling RepaGyn and Proktis-M in Canada until 2032.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Meagen moved to Vancouver in 2019 after splitting her time between Australia and Southeast Asia for three years. She worked simultaneously as a freelancer and childcare provider before landing her role as an Investment Market Content Specialist at the Investing News Network.
Meagen has studied marketing, developmental and cognitive psychology and anthropology, and honed her craft of writing at Langara College. She is currently pursuing a degree in psychology and linguistics. Meagen loves writing about the life science, cannabis, tech and psychedelics markets. In her free time, she enjoys gardening, cooking, traveling, doing anything outdoors and reading.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Meagen moved to Vancouver in 2019 after splitting her time between Australia and Southeast Asia for three years. She worked simultaneously as a freelancer and childcare provider before landing her role as an Investment Market Content Specialist at the Investing News Network.
Meagen has studied marketing, developmental and cognitive psychology and anthropology, and honed her craft of writing at Langara College. She is currently pursuing a degree in psychology and linguistics. Meagen loves writing about the life science, cannabis, tech and psychedelics markets. In her free time, she enjoys gardening, cooking, traveling, doing anything outdoors and reading.
Learn about our editorial policies.